Moeller, F. Gerard; Barratt, Ernest S.; Dougherty, Donald M.; Schmitz, Joy M.; Swann, Alan C. (November 2001). "Psychiatric Aspects of Impulsivity". American Journal of Psychiatry. 158 (11): 1783–1793. doi:10.1176/appi.ajp.158.11.1783. PMID 11691682. Chamberlain, Samuel R; Sahakian, Barbara J (May 2007). "The neuropsychiatry of impulsivity". Current Opinion in Psychiatry. 20 (3): 255–261. doi:10.1097/YCO.0b013e3280ba4989. PMID 17415079. S2CID 22198972. External links
 Media related to Impulsivity at Wikimedia Commons
Impulsive Info
However, some other regulatory authorities did not agree with the FDA decision, with Japans Pharmaceuticals and Medical Devices Agency stating in 2011 that the "risk-benefit balance of gemtuzumab ozogamicin has not changed from its state at the time of approval".In 2017, Pfizer reapplied for US and EU approval, based on a meta-analysis of prior trials and results of the ALFA-0701 clinical trial, an open-label Phase III trial in 280 older people with AML. In September 2017, gemtuzumab ozogamicin was approved again for use in the United States and in the European Union. See also
Inotuzumab ozogamicin

References
Further reading
AusPAR: Gemtuzumab ozogamicin. Therapeutic Goods Administration (TGA) (Report). October 2020. External links
"Gemtuzumab ozogamicin". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT00372593 for "Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia" at ClinicalTrials.gov